

STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bill J. Crouch Cabinet Secretary Bureau for Medical Services Pharmacy Services 350 Capitol Street – Room 251 Charleston, West Virginia 25301-3706 Telephone: (304) 558-1700 Fax: (304) 558-1542

Cynthia E. Beane Commissioner

Pharmaceutical and Therapeutics Committee OCTOBER 28, 2020

Location: WebEx only Time: Open Session 9:00 AM – 12:00 PM and 2:00 PM – 5:00 PM Time: Executive Session 12:00 PM – 2:00 PM Charleston, WV 25301 (304) 558-1700

MINUTES

Committee Members Present:

Tom Kines, RPh, Chair Chris Terpening, PharmD, PhD, Vice-Chair Toni DiChiacchio, DNP (dekiakio) Philip Galapon, MD FAAFP David Gloss, MD Bradley Henry, MD John Bernabei, RPh (JJ) Charles Rohrbaugh, RPh

Absent:

Kelli Lynn Jennings, PharmD Heather Jones, PA-C Hani Nahza, MD

Division of Medicaid Staff Present:

Gail Goodnight, Rebate Manager Bill Hopkins, Operations Manager Lori Moles, Appeals Pharmacist Priya Shah, DUR Coordinator Doug Sorvig, Data Analyst Brian Thompson, PharmD, MS, Director

Contract Staff Present:

Change Healthcare Ryan Fell, PharmD Robert Dinwiddie, PharmD Ashleigh Holeman, PharmD Laureen Biczak, MD Steve Liles, PharmD

Other Contract / State Staff Present:

I. Call to Order

Tom Kines, Chairman, called the meeting to order at 9:03 AM.

II. Welcome and Introductions

Tom Kines, welcomed all present to the committee meeting. Committee members, Bureau of Medical Services staff, and Change Healthcare staff introduced themselves.

III. Housekeeping Items / Updates

A. Approval of the August, 26, 2020 Minutes

The Committee moved to approve the August 26, 2020 Meeting minutes. All were in favor with no objections or revisions.

B. PDL Compliance / Generic Percent Report Updates

Ryan Fell provided an explanation of the PDL Compliance and Generic Percent reports.

- Ryan Fell reviewed the Generic Percent Report; overall generic utilization for Q3 2020 was 85.7%
- Ryan Fell reviewed the PDL Compliance Report; overall compliance for Q3 2020 was 91.8%

IV. Drug Class Announcements

Change Healthcare recommended that the following classes be extracted:

- Acne Agents, Topical
- Antibiotics, Vaginal
- Anticonvulsants
- Antihyperuricemics
- Antimigraine Agents, CGRP Inhibitors
- Anitretrovirals
- Bronchodilators, Beta Agonists
- Cytokine & Cam Antagonists
- Gluocorticoids, Inhaled
- Hypoglycemics, Insulins and Related Agents
- Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors
- Immunomodulators, Atopic Dermatitis
- Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents
- Laxatives and Cathartics
- Lipotropics, Other (Non-Statins)
- MABS-Anti-IL, Anti IgE

- Multiple Sclerosis Agents
- Neuropathic Pain
- Ophthalmics for Allergic Conjunctivitis
- Otic Antibiotics
- Sedative Hypnotics
- Steroids, Topical
- Stimulants & Related Agents

V. First Round of Extractions

Additional extractions presented by Committee members:

- Analgesics, Narcotics- Long Acting (Non-Parenteral)-Philip Galapon
- COPD Agents-Bradley Henry
- Hypoglycemics, GLP-1 Agonists -Bradley Henry
- Opiate Dependence Treatments-Charles Rohrbaugh

VI. Public Comments

Public comments for this meeting were only accepted in writing. Written statements were provided to State and Committee members for review prior to this meeting and are available to the public on the State's website.

VII. Second Round of Extractions

Additional extractions presented by Committee members:

• None

VIII. Motion for All Non-Extracted Categories to be Approved as Proposed

- Alzheimer's Agents
- Analgesics, Narcotics- Short Acting (Non-Parenteral)
- Androgenic Agents
- Anesthetics, Topical
- Angiotensin Modulators
- Antianginal & Anti-Ischemic
- Antibiotics, GI & Related Agents
- Antibiotics, Inhaled
- Antibiotics, Topical
- Anticoagulants
- Antidepressant-Other
- Antidepressants- SSRIs
- Antiemetics
- Antifungals, Oral
- Antifungals, Topical
- Antihemophilia Factor Agents

- Antihypertensives, Sympatholytics
- Antimigraine Agents, Other
- Antimigraine Agents, Triptans
- Antiparasitics, Topical
- Antiparkinson's Agents
- Antipsoriatics, Topical
- Antipsychotics, Atypical
- Antivirals, Oral
- Antivirals, Topical
- Beta Blockers
- Bladder Relaxant Preparations
- Bone Resorption Suppression & Related Agents
- BPH Treatments
- Calcium Channel Blockers
- Cephalosporins & Related Antibiotics

- Epinephrine, Self-Injected
- Erythropoiesis Stimulating
 Proteins
- Fluoroquinolones (Oral)
- Growth Hormones
- H. Pylori Treatment
- Hepatitis B Treatments
- Hepatitis C Treatments
- Hyperparathyroid Agents
- Hypoglycemics, Biguanides
- Hypoglycemics, DPP-4 Inhibitors
- Hypoglycemics, Meglitinides
- Hypoglycemics, Miscellaneous Agents
- Hypoglycemics, TZDs
- Immunomodulators, Genital Warts & Actinic Keratosis Agents
- Immunosuppressive, Oral
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Lipotropics, Statins
- Macrolides
- NSAIDs
- Ophthalmic Antibiotics

- Ophthalmic Antibiotics/Steroid Combinations
- Ophthalmics, Anti-Inflammatories-Immunomodulators
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma Agents
- PAH Agents Endothelin Receptor Antagonists
- PAH Agents Guanylate Cyclase Stimulator
- PAH Agents PDE5s
- PAH Agents Prostacyclins
- Pancreatic Enzymes
- Phosphate Binders
- Pituitary Suppressive Agents, LHRH
- Platelet Aggregation Inhibitors
- Progestational Agents
- Progestins for Cachexia
- Proton Pump Inhibitors
- Skeletal Muscle Relaxants
- Tetracyclines
- Ulcerative Colitis Agents
- Vasodilators, Coronary

A motion was made and seconded to accept all non-extracted categories as presented by Change Healthcare. All members were in favor and the motion was approved.

IX. Break/Lunch and Executive Session

The committee adjourned at 9:16 AM for Executive Session and lunch until afternoon session.

X. Extracted Therapeutic Category Reviews/Committee Recommendations

Tom Kines, Chairman, called the second open session to order atPM

A. Acne Agents, Topical

ACNE AGENTS, TOPICALAP

CLASS PA CRITERIA: Non-preferred agents require a thirty (30) day trial of one (1) preferred retinoid and two (2) unique chemical entities in two (2) other subclasses, including the generic version of the requested non-preferred product, before they will be approved, unless one (1) of the exceptions on the PA form is present.

In cases of pregnancy, a trial of retinoids will not be required. For members eighteen (18) years of age or older, a trial of retinoids will not be required. Acne kits are non-preferred.

Specific Criteria for sub-class will be listed below. NOTE: Non-preferred agents in the Rosacea sub-class are available <u>only on appeal</u> and require at least a 30day trial of all preferred agents in that sub-class.

ANTI-INFECTIVE		
ACZONE (dapsone	AKNE-MYCIN (erythromycin)	
CLINDAGEL (clindamycin) clindamycin lotion, medicated swab, solution	ARAZLO (tazarotene) AZELEX (azelaic acid)	
erythromycin gel, solution	CLEOCIN-T (clindamycin)	
	CLINDACIN ETZ kit, medicated swab	
	(clindamycin) CLINDACIN P (clindamycin)	
	CLINDACIN PAC (clindamycin)	
	clindamycin gel, foam	
	dapsone ERYGEL (erythromycin)	
	erythromycin medicated swab	
	EVOCLIN (clindamycin)	
	FABIOR (tazarotene) KLARON (sulfacetamide)	
	OVACE/PLUS (sulfacetamide)	
	sodium sulfacetamide 10% cleansing gel	
	sulfacetamide cleanser sulfacetamide cleanser ER	
	sulfacetamide shampoo	
	sulfacetamide suspension	
DIFFERIN (adapalene)	RETINOIDS adapalene	In addition to the Class Criteria: PA required for members
RETIN-A (tretinoin)	AKLIEF CREAM (trifarotene)	eighteen (18) years of age or older.
RETIN-A MICRO (tretinoin)	ALTRENO LOTION (tretinoin)	
TAZORAC (tazarotene) PREFERRED AGENTS	ATRALIN (tretinoin) NON-PREFERRED AGENTS	PA CRITERIA
THEI ERRED AGEN TO	AVITA (tretinoin)	TAGATEAA
	PLIXDA SOLUTION (adapalene)	
	tazarotene cream tretinoin cream, gel	
	tretinoin gel micro	
benzoyl peroxide cleanser Rx & OTC, 10%	KERATOLYTICS BENZEFOAM ULTRA (benzoyl peroxide)	
cream OTC, gel Rx & OTC, lotion OTC,	BP 10-1 (benzoyl peroxide)	
wash OTC	BPO (benzoyl peroxide) PANOXYL-8 OTC (benzoyl peroxide)	
PANOXYL-4 OTC (benzoyl peroxide)	SULPHO-LAC (sulfur)	
	COMBINATION AGENTS	
ACANYA (clindamycin phosphate/benzoyl peroxide)	adapalene-benzoyi peroxide* AVAR/-E/LS (sulfur/sulfacetamide)	In addition to the Class Criteria: Non-preferred combination agents require thirty (30) day trials of the corresponding
BENZAMYCIN PAK (benzoyl peroxide/	BENZACLIN GEL (benzoyl peroxide/ clindamycin)	preferred single agents before they will be approved.
erythromycin)	benzoyl peroxide/clindamycin gel (all generics	
benzoyl peroxide/clindamycin gel (generic DUAC only)	other than DUAC) benzoyl peroxide/urea	*PA required for combination agents with Retinoid products for
EPIDUO (adapalene/benzoyl peroxide)*	CERISA (sulfacetamide sodium/sulfur)	members eighteen (18) years of age or older.
EPIDUO FORTE (adapalene/benzoyl	CLARIFOAM EF (sulfacetamide/sulfur)	
peroxide)* ONEXTON (clindamycin phosphate/benzoyl	CLENIA (sulfacetamide sodium/sulfur) clindamycin-tretinoin gel	
peroxide)	DUAC (benzoyl peroxide/clindamycin)	
sulfacetamide sodium/sulfur suspension	erythromycin/benzoyl peroxide	
ZIANA (clindamycin/ <u>tretinoin)*</u>	NEUAC (clindamycin phosphate/benzoyl peroxide)	
	PRASCION (sulfacetamide sodium/sulfur)	
	SE 10-5 SS (sulfacetamide/sulfur)	
	SSS 10-4 (sulfacetamide /sulfur) SSS 10-5 foam (sulfacetamide /sulfur)	
	sulfacetamide sodium/sulfur cloths, lotion, pads	
	sulfacetamide/sulfur wash/cleanser	
	sulfacetamide/sulfur wash kit sulfacetamide sodium/sulfur/ urea	
	SUMADAN/XLT (sulfacetamide/sulfur)	
	SUMAXIN/TS (sulfacetamide sodium/sulfur) VELTIN (clindamycin/tretinoin)*	
	ROSACEA AGENTS	
FINACEA GEL (azelaic acid)	AMZEEQ FOAM (minocycline)	Subclass criteria: Non-preferred agents are available only on

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Henry and seconded by Dr. Galapon, all were in favor and the motion was approved.

B. Antibiotics, Vaginal

|--|

 CLASS PA CRITERIA: Non-preferred agents require trials of each chemically unique preferred agent at the manufacturer's recommended duration, before they will be approved, unless one (1) of the exceptions on the PA form is present.

 CLEOCIN OVULE (clindamycin)
 AVC (sulfanilamide)

 CLINDESS (clindamycin)
 CLEOCIN CREAM (clindamycin)

metronidazole NUVESSA (metronidazole) CLEOCIN CREAM (dindamycin) clindamycin cream METROGEL (metronidazole) SOLOSEC (secnidazole) VANDAZOLE (metronidazole)

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Terpening and seconded by Dr. Galapon, all were in favor and the motion was approved

C. Anticonvulsants

ANTICONVULSANTS

CLASS PA CRITERIA: For a diagnosis of seizure disorder, non-preferred agents require a fourteen (14) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present; patients currently on established therapies shall be grandfathered.

For all other diagnoses, non-preferred agents require a thirty (30) day trial of a preferred agent in the same sub-class before they will be approved, unless one (1) of the exceptions on the PA form is present.

In situations where AB-rated generic equivalent products are available, "Brand Medically Necessary" must be hand-written by the prescriber on the prescription for the brand name product to be reimbursed.

ADJUVANTS THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	LAMICTAL ODT (lamotrigine) LAMICTAL XR (lamotrigine) lamotrigine dose pack lamotrigine ER OXTELLAR XR (oxcarbazepine) POTIGA (ezogabine) QUDEXY XR (topiramate <u>ER)**</u> SABRIL (vigabatrin) SPRITAM (levetiracetam) STAVZOR (valproic acid) TEGRETOL TABLETS (carbamazepine) TEGRETOL TABLETS (carbamazepine) tiagabine TOPAMAX (topiramate) TRILEPTAL SUSPENSION and TABLETS (oxcarbazepine) TROKENDI XR (topiramate)** vigabatrin tablet/powder pack XCOPRI (cenobamate) ZONEGRAN (zonisamide)	

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Gloss, all were in favor and the motion was approved

D. Antihyperuricemics

ANTIHYPERURICEMICS

CLASS PA CRITERIA: Non-preferred agents require a thirty (30) day trial of one (1) of the preferred agents for the prevention of gouty arthritis attacks (colchicine/probenecid, probenecid, or allopurinol) before they will be approved, unless one (1) of the exceptions on the PA form is present. ANTIMITOTICS

COLCRYS (colchicine)

colchicine capsules colchicine tablets MITIGARE (colchicine) GLOPERBA (colchicine) In the case of acute gouty attacks, a ten (10) day supply (twenty (20) capsules) of the preferred agent(s) in this subclass will be authorized per ninety (90) days.

Gloperba may only be authorized for those who are unable to ingest solid dosage forms due to documented <u>oral-motor</u> difficulties or dysphagia.

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Henry, all were in favor and the motion was approved

E. Antimigraine Agents, CGRP Inhibitors

CLASS PA CRITERIA: All agents require a p	rior authorization. Full PA criteria may be found o	n the <u>PA Criteria</u> page by clicking the hyperlink. Non-preferred
	THERAPEUTIC DRUG CLAS	S
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
agents require a 90-day trial of all preferred agents.		
AIMOVIG (erenumab) AJOVY (fremanezumab)	EMGALITY (galcanezumab) 120mg/mL EMGALITY (galcanezumab) 300mg/3 mL*	*Emgality 300 mg/3 mL requires review by the Medical Director and is available only on appeal.

A motion to approve the recommended changes (as above) by Change Healthcare was made by Charlie Rohrbaugh and seconded by Dr. Henry, all were in favor and the motion was approved

F. Antiretrovirals

ANTIRETROVIRALSAP	
	COMBINATION PRODUCTS - NRTIS
abacavir/lamivudine CIMDUO (lamivudine/tenofovir) lamivudine/zidovudine	abacavir/lamivudine/zidovudine COMBIVIR (lamivudine/zidovudine) EPZICOM (abacavir/lamivudine) TEMIXY'S (lamivudine/tenfovir) TRIZIVIR (abacavir/lamivudine/zidovudine)

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Henry, all were in favor and the motion was approved

G. Bronchodilators, Beta Agonists

BRONCHODILATORS, BETA AGONISTAP

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of each chemically distinct preferred agent in their corresponding sub-class unless one (1) of the exceptions on the PA form is present.

PROAIR HFA (albuterol) PROAIR RESPICLICK (albuterol) VENTOLIN HFA (albuterol) INHALERS, SHORT-ACTING albuterol HFA MAXAIR (pirbuterol) PROAIR DIGIHALER (albuterol) PROVENTL HFA (albuterol) XOPENEX HFA (levalbuterol)

Dr. Henry brought forth a recommendation to move Ventolin HFA to preferred. A motion to approve the recommended changes (as above) by Change Healthcare and to move Ventolin HFA to preferred was made by Dr. Galapon and seconded by Dr. Henry, all were in favor and the motion was approved

H. Cytokine & Cam Antagonists

CLASS PA CRITERIA: Non-preferred agents require ninety (90) day trials of both Humira and Enbrel unless one (1) of the exceptions on the PA form is present. For FDA-approved indications, an additional ninety (90) day trial of Cosentyx will also be required. Patients stabilized for at least 6-months on their existing non-preferred regimen shall be grandfathered (provided the current therapy is for a labeled indicator). All off-label requests require review by the Medical Director.

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ENBREL (etanercept)* HUMIRA (adalimumab)*	CIMZIA (certolizumab pegol) REMICADE (infliximab) RENFLEXIS (infliximab) SIMPONI subcutaneous (golimumab)	*Full PA criteria may be found on the <u>PA Criteria</u> page by clicking the hyperlink.
	OTHERS	
TALTZ (ixekizumab) XELJANZ (tofacitinib)**	ACTEMRA subcutaneous (tocilizumab) COSENTYX (secukinumab)* ENTYVIO (vedolizumab) ILARIS (canakinumab) ILUMYA (tildrakizumab) KEVZARA (sarilumab) KINERET (anakinra) OLUMIANT (baricitinib) ORENCIA subcutaneous (abatacept) OTEZLA (apremilast) RINVOQ ER (upadacitinib) SILIQ (brodalumab) SKYRIZI (risankizumab) STELARA subcutaneous (ustekinumab) TREMFYA (guselkumab) XELJANZ XR (tofacitinib)	*Cosentyx will be authorized for treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis only after inadequate response to a ninety (90) day trial of one preferred agent. **Xeljanz is preferred for treatment of rheumatoid arthritis and ulcerative colitis only.

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Gloss, all were in favor and the motion was approved

I. Glucocorticoids, Inhaled


GLUCOCORTICOIDS, INHALEDAP

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of each chemically unique preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present. GLUCOCORTICOIDS ASMANEX TWISTHALER (mometasone) AEROSPAN (flunisolide)' *Pulmicort Respules are only preferred for children up to nine budesonide nebulizer 0.5 mg/2 ml & 0.25 mg/2 ALVESCO (ciclesonide) (9) years of age. For patients nine (9) and older, prior ARMONAIR RESPICLICK (fluticasone) ml solution authorization is required and will be approved only for a THERAPEUTIC DRUG CLASS PREFERRED AGENTS NON-PREFERRED AGENTS **PA CRITERIA** FLOVENT DISKUS (fluticasone) ARNUITY ELLIPTA (fluticasone) diagnosis of severe nasal polyps. FLOVENT HEA (fluticasone) ASMANEX HFA (mometasone) PULMICORT NEBULIZER SOLUTION PULMICORT FLEXHALER (budesonide) **Aerospan will be authorized for children ages 6 through 11 (budesonide) years old without a trial of a preferred agent. QVAR REDIHALER (beclomethas GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS ADVAIR DISKUS (fluticasone/salmeterol) AIRDUO RESPICLICK (fluticasone/salmeterol) ADVAIR HFA (fluticasone/salmeterol) BREO ELLIPTA (fluticasone/vilanterol) DULERA (mometasone/formoterol) SYMBICORT/budesonide/formoterol) Imeterol WIXELA (fluticasone/salmeterol)

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Terpening, all were in favor and the motion was approved

J. Hypogclycemics, Insulins & Related Agents HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

CLASS PA CRITERIA: Non-preferred agents require a ninety (90) day trial of a pharmacokinetically similar agent before they will be approved, unless one (1) of the exceptions on the PA form is present.



A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Terpening, all were in favor and the motion was approved

K. Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors

HYPOGLYCEMICS, SGLT2 INHIBITORSCL

CLASS PA CRITERIA: Non-preferred agents will only be approved (in 6-month intervals) if ALL of the following criteria has been met:

1) Current A1C must be submitted. Agents in this class will not be approved for patients with a starting A1C of less than (<) 7%.

- 2) Documentation demonstrating 90 days of compliance on all current diabetic therapies is provided.
- 3) Documentation demonstrating treatment failure with all unique preferred agents in the same class

Re-authorizations will require documentation of <u>continued</u> compliance on all diabetic therapies and A1C levels must reach goal, (either an A1C of ≤8%, or demonstrated continued improvement).

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
	TRIJARDY XR (empagliflozin/inagliptin/metformin) QTERN (dapagliflozin/saxagliptin) XIGDUO XR (dapagliflozin/metformin)	

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Henry and seconded by Dr. Galapon, all were in favor and the motion was approved

L. Immunomodulators, Atopic Dermatitis

 IMMUNOMODULATORS, ATOPIC DERMATITIS

 CLASS PA CRITERIA: Non-preferred agents require 30-day trial of a medium to high potency topical corticosteroid AND all preferred agents in this class unless one (1) of the exceptions on the PA form is present. Requirement for topical corticosteroids may be excluded with involvement of sensitive areas such as the face and skin folds.

 ELIDEL (pimecrolimus)
 DUPIXENT (dupilumab)*
 *Full PA criteria for Dupixent may be found on the <u>PA Criteria</u> page by clicking the hyperlink

 PROTOPIC (tacrolimus)
 DUPIXENT (dupilumab)*
 *Full PA criteria for Dupixent may be found on the <u>PA Criteria</u> page by clicking the hyperlink

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Henry and seconded by Dr. Galapon, all were in favor and the motion was approved

M. Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents


IRRITABLE BOWEL SYNDROME/SHORT BOWEL SYNDROME/SELECTED GI AGENTS CL

CLASS PA CRITERIA: All agents are approvable only for patients age eighteen (18) and older. See below for additional sub-class criteria.

CONSTIPATION		
AMITIZA (lubiprostone) MOVANTIK (naloxegol) LINZESS (linaclotide)	LINZESS 72 mcg (linactotide) MOTEGRITY (prucalopride) RELISTOR INJECTION (methylnaltrexone) RELISTOR TABLET (methylnaltrexone) SYMPROIC (naldemedine) TRULANCE (plecanatide) ZELNORM (tegaserod maleate)	All agents in this subclass require documentation of the current diagnosis and evidence that the patient has failed to find relief with dietary modification and a fourteen (14) day trial of an osmotic laxative. No agent shall be approved to treat opioid induced constipation (OIC) without evidence of at least 90-days of opioid use preceding the request. Continuation of coverage shall be granted with evidence of continuous and concurrent opioid use.
		Agents may be authorized only for their FDA-approved labeled indication. The following agent-specific criteria shall also apply:
		<u>Motegrity</u> requires a 30-day trial of both Amitiza and Linzess. <u>Relistor</u> and <u>Symproic</u> are indicated for OIC and require thirty (30) day trials of both Movantik and Amitiza.
		<u>Trulance</u> requires thirty (30) day trials of both Amitiza and Linzess, however for the indication of IBS-C in <u>males</u> , a trial of Amitiza is not required.
N motion to approve the recommended changes (as above) by Change Healtheare was		

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Henry, all were in favor and the motion was approved

N. Laxatives and Cathartics



A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Charlie Rohrbaugh, all were in favor and the motion was approved

O. Lipotropics, Other (Non-Statins)

LIPOTROPICS, OTHER (Non-statins)

CLASS PA CRITERIA: Non-preferred agents require a twelve (12) week trial of a preferred agent before they will be approved, unless one (1) of the exceptions on the PA form is present.

PCSK-9 INHIBITORS/BEMPEDOIC ACID		
PRALUENT (alirocumab)* REPATHA (evolocumab)* NEXLETOL (bempedoic acid)* NEXLIZET (bempedoic acid/ezetimibe)*	*Full PA criteria may be found on the <u>PA Criteria</u> page by clicking the hyperlink.	

A motion to approve the recommended changes (as above) by Change Healthcare was made by Charlie Rohrbaugh and seconded by Dr. Terpening, all were in favor and the motion was approved

P. MABS-Anti-IL, Anti IgE

MADS, AN I-LINE			
CLASS PA CRITERIA: Full PA Criteria may be	CLASS PA CRITERIA: Full PA Criteria may be found on the PA Criteria page by clicking the hyperlink.		
XOLAIR (omalizumab)	DUPIXENT (dupilumab) FASENRA (benralizumab) FASENRA PEN (benralizumab) NUCALA SYRINGE/VIAL (mepolizumab) NUCALA AUTO INJECTOR (mepolizumab)		

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Charlie Rohrbaugh, all were in favor and the motion was approved

- -

in be approved, uness one (1) of the exce	otions on the PA form is present. NON-INTERFERONS	
AUBAGIO (teriflunomide)** Iaifampridine ER COPAXONE 20 mg (glatiramer) Imethyl fumerate **** BILENYA (fingolimod)	AMPYRA (dalfampridine)* COPAXONE 40 mg (glatiramer)*** glatiramer GLATOPA (glatiramer) MAYZENT (siponimod)**** MAVENCLAD (cladribine) TECFIDERA (dimethyl <u>fumarate)*</u> **** VUMERITY (diroximel) ZINBRYTA (daclizumab)	In addition to class PA criteria, the following condition and criteria may also apply: *Ampyra and dalfampridine ER require the following addition criteria to be met: 1. Diagnosis of multiple sclerosis and 2. No history of seizures and 3. No evidence of moderate or severe renal impairment **Aubagio requires the following additional criteria to be met: 1. Diagnosis of relapsing multiple sclerosis and 2. Measurement of transaminase and bilirubin leve within the (6) months before initiation of therapy an ALT levels at least monthly for six (6) months after initiation of therapy and 3. Complete blood cell count (CBC) within six (1)
THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
		 months before initiation of therapy and Female patients must have a negative pregnancy terbefore initiation of therapy and be established on reliable method of contraception if appropriate and Patient is between eighteen (18) up to sixty-five (69 years of age and Negative tuberculin skin test before initiation of therapy ***Copaxone 40mg will only be authorized for documente injection site issues.
		beyond the diagnosis for patients with documented <u>secondar</u> progressive MS.
		 *****Tecfidera and dimethyl fumerate require the following additional criteria to be met: 1. Diagnosis of relapsing multiple sclerosis and 2. Complete blood count (CBC) within six (6) months initiation of therapy and six (6) months after initiation and

approve the recommended changes (as above) by Change Healthcare and to move dimethyl fumerate to preferred was made by Charlie Rohrbaugh and seconded by Dr. Gloss, all were in favor and the motion was approved

R. **Neuropathic Pain** NEUROPATHIC PAIN CLASS PA CRITERIA: Non-preferred agents require a thirty (30) day trial of a preferred agent in the corresponding dosage form (oral or topical) before they will be approved, unless one (1) of the exceptions on the PA form is present. CYMBALTA (duloxetine) DRIZALMA SPRINKLE (duloxetine)* capsaicin OTC *Drizalma SPRINKLE will only be authorized for those who are duloxetine unable to indest solid dosade forms due to documented oralgabapentin lidocaine patch GRALISE (gabapentin)** HORIZANT (gabapentin) motor difficulties or dysphagia. pregabalin capsule ZTLIDO PATCH (lidocaine) IRENKA (duloxetine) LIDODERM (lidocaine) **Gralise will be authorized only if the following criteria are met: LYRICA CR (pregabalin)*** Diagnosis of post herpetic neuralgia and 1. LYRICA SOLUTION (pregabalin)*** Trial of a tricyclic antidepressant for a least thirty (30) 2. NEURONTIN (gabapentin)^{AP} days and QUTENZA (capsaicin) 90-day trial of gabapentin immediate release formulation (positive response without adequate 3. SAVELLA (milnacipran)**** LYRICA CAPSULE (pregabalin) duration) and


A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Terpening, all were in favor and the motion was approved

S. Ophthalmic OPHTHALMICS FOR ALLERGIC C	cs for Allergic Conjuncti onjunctivitisa	vitis	
CLASS PA CRITERIA: Non-preferred agents re of the exceptions on the PA form is present.	equire thirty (30) day trials of three (3) preferred chemi-	cally unique agents before they will be approved, unless one (1)	
ALAWAY (ketotifen) ALREX (loteprednol) BEPREVE (bepotastine) cromolyn ketotifen LASTACAFT (alcaftadine) olopatadine 0.1% (Generic PATANOL labeler 61314 only) ZADITOR OTC (ketotifen)	ALAMAST (pemirolast) ALOCRIL (nedocromil) ALOMIDE (lodoxamide) azelastine CROLOM (cromolyn) ELESTAT (epinastine) EMADINE (epinastine) Epinastine LUMIFY (brimonidine)		
	THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA	
	olopatadine 0.1% (all formulations except Generic PATANOL labeler 61314) olopatadine 0.2% (all labelers) OPTICROM (cromolyn) OPTIVAR (azelastine) PATADAY (olopatadine) PATANOL (olopatadine) PAZEO (olopatadine) ZERVIATE (cetirizine)		

A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Terpening and seconded by Dr. Galapon, all were in favor and the motion was approved

Τ. **Otic Antibiotics**

OTIC ANTIBIOTICSAP



A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Terpening and seconded by Dr. Galapon, all were in favor and the motion was approved


U. Sedative Hypnotics

SEDATIVE HYPNOTICS

CLASS PA CRITERIA: Non-preferred agents require thirty (30) day trials of all preferred agents in BOTH sub-classes before they will be approved, unless one (1) of the exceptions on the PA form is present. All agents except melatonin will be limited to fifteen (15) tablets in a thirty (30) day period. NOTE: WV Medicaid covers melatonin up to a maximum dose of 9 mg/day without a PA. Melatonin labeler code 51645 is preferred if available, however all NDCs are payable.

	OTHERS	
Melatonin ROZEREM (rametteon) zolpidem 5, 10 mg	OTHERS AMBIEN (zolpidem) AMBIEN CR (zolpidem) BELSOMRA (suvorexant) chioral hydrate DAYVIGO (lemborexant) EDLUAR (zolpidem) eszopicione HETLIOZ (tasimetecon) ^{CL*} INTERMEZZO (zolpidem) LUNESTA (eszopicione) rameteon SILENOR (doxepin) SOMNOTE (chioral hydrate) SONATA (zalepion) zalepion zolpidem ER 6.25, 12.5 mg ZOLPIMIST (zolpidem)	Strengths of zolpidem that are non-preferred (6.25 and 12.5 mg) must be created by combining or splitting the preferred doses (5 and 10 mg) of zolpidem, if appropriate. For treatment naïve female patients, zolpidem and zolpidem ER maximum dosages will be limited to 5 mg and 6.25 mg respectively per day. *Full PA criteria may be found on the <u>PA Criteria</u> page by clicking the hyperlink.

Dr. Gloss made a motion to add a non-benzo alternative to the preferred list and recommended Rozerem be moved to preferred. A motion to approve the recommended changes (as above) by Change Healthcare and to move Rozerem to preferred was made by Dr. Gloss and seconded by Dr. Galapon, all were in favor and the motion was approved




A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Terpening and seconded by Dr. Gloss, all were in favor and the motion was approved

W. Stimulants & Related Agent

STIMULANTS AND RELATED AGENTS

CLASS PA CRITERIA: A PA is required for adults eighteen (18) years of age or older.

Non-preferred agents require a thirty (30) day trial of at least one preferred agent in the same subclass and with a similar duration of effect and mechanism of action, unless one (1) of the exceptions on the PA form is present. NOTE: Non-preferred agents will NOT be "grandfathered" for adults. Children under the age of 18 may continue their current therapy until the end of the school year after which they will be required to switch to a preferred agent.



A motion to approve the recommended changes (as above) by Change Healthcare was made by Dr. Galapon and seconded by Dr. Terpening, all were in favor and the motion was approved

X. Analgesics, Narcotics- Long Acting (Non-Parenteral)

THERAPEUTIC DRUG CLASS		
PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ANALGESICS, NARCOTIC LONG A CLASS PA CRITERIA: Non-preferred agents re requested non-preferred agent (if available) befor the requested non-preferred brand agent, then a	NON-PREFERRED AGENTS CTING (Non-parenteral) ^{AP} quire six (6) day trials of two (2) chemically distinct pi e they will be approved, unless one (1) of the excepti nother generic non-preferred agent must be trialed i	

The above category was recommended for extraction by Dr. Galapon who recommended moving Xtampza ER to preferred for an additional long-acting narcotic option. A motion to approve the recommended changes was made by Dr. Galapon and seconded by Charlie Rohrbaugh, all were in favor and the motion was approved.

Y. COPD Agents

The above category was recommended for extraction by Dr. Henry. There was no change to this category. A motion to approve the category as is was made by Dr. Henry and seconded by Dr. Galapon, all were in favor and the motion was approved.

Z. Hypoglycemics, GLP-1 Agonists-Dr. Henry

The above category was recommended for extraction by Dr. Henry. There was no change to this category. A motion to approve the category as is was made by Dr. Henry and seconded by Dr. Galapon, all were in favor and the motion was approved.

AA. Opiate Dependence Treatments-Charlie Rohrbaugh

The above category was recommended for extraction by Charlie Rohrbaugh. There was no change to this category. A motion to approve the category as is was made by Charlie Rohrbaugh and seconded by Dr. Galapon, all were in favor and the motion was approved.

XI. Next Meeting

The next P&T Committee Meeting is scheduled for January 27th, 2021, from 2:00 PM-5:00 PM, Virtual Meeting

XII. Other Business

There was no other business discussed at this time.

XIII. Adjournment

The Committee adjourned the meeting at 2:26 PM.